You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,599,704


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,599,704
Title: ErbB2/neu targeted ribozymes
Abstract:An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of breast cancer.
Inventor(s): Thompson; James D. (Boulder, CO), Draper; Kenneth G. (Boulder, CO)
Assignee: Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:08/435,350
Patent Claims:1. An enzymatic RNA molecule which specifically cleaves mRNA produced from the gene ErbB2/neu.

2. The enzymatic RNA molecule of claim 1 which specifically cleaves the RNA sequence comprising any of SEQ. ID. NOS. 1-118, wherein said nucleic acid is in a hepatitis Delta virus configuration.

3. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule is in a hammerhead motif.

4. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA nucleic acid molecule is in a hairpin, hepatitis Delta virus, group 1 intron, or RNAseP RNA motif.

5. The enzymatic RNA of any of claims 1-4, wherein said enzymatic RNA molecule nucleic acid comprises between 5 and 23 bases complementary to said mRNA.

6. The enzymatic RNA molecule of any of claims 1-4, wherein said enzymatic RNA molecule comprises between 10 and 18 bases complementary to said mRNA.

7. The enzymatic RNA molecule of claim 1, which specifically cleaves RNA sequence comprising any of SEQ. ID. NOS. 1-3, 6-16, 19, 20, 22-25, 27-37, 39-42, 45, 47-51, 53-56, 59-68, 70-75, 77, 78, 80, 83-87, 89-94, 96, 97, 99-107, 109, and 111-118, wherein said enzymatic RNA molecule is in a hammerhead configuration.

8. The enzymatic RNA molecule nucleic acid of any of claims 1-4 or 7, wherein said enzymatic RNA molecule comprises at least one sugar modification.

9. The enzymatic RNA molecule of any of claims 1-4 or 7, wherein said enzymatic RNA molecule comprises at least one base modification.

10. The enzymatic RNA molecule of any of claims 1-4 or 7, wherein said enzymatic RNA molecule comprises at least one phosphate modification.

11. The enzymatic RNA molecule of claim 10, wherein said phosphate modification is a phosphorothioate.

12. An expression vector comprising a nucleic acid encoding the enzymatic RNA molecule of any of claims 1-4, in a manner which allow expression of that enzymatic RNA molecule within a mammalian cell in vitro.

13. A mammalian cell in vitro comprising an enzymatic RNA molecule of any of claims 1-4.

14. The cell of claim 3, wherein said cell is a human cell.

Details for Patent 5,599,704

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2014-02-04
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2014-02-04
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2014-02-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.